论文部分内容阅读
目的探讨分析羟乙基淀粉40氯化钠注射液治疗进展性脑梗死的临床疗效。方法 60例进展性脑梗死患者,按照治疗方法的不同将其分为对照组(给予常规治疗)以及联合治疗组(在对照组的基础上给予羟乙基淀粉40氯化钠注射液联合低分子肝素钙治疗),每组30例。比较两组患者治疗前后的美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数、治疗效果以及不良反应发生率。结果治疗前,两组患者NIHSS评分比较差异无统计学意义(P>0.05)。治疗后7、14 d,联合治疗组NIHSS评分均低于对照组,差异具有统计学意义(P<0.05)。治疗前,两组患者Barthel指数比较差异无统计学意义(P>0.05)。治疗后3、6个月,联合治疗组患者Barthel指数均高于对照组,差异具有统计学意义(P<0.05)。联合治疗组总有效率为96.7%,高于对照组的80.0%,差异具有统计学意义(P<0.05)。联合治疗组不良反应发生率为3.3%,低于对照组的20.0%,差异具有统计学意义(P<0.05)。结论羟乙基淀粉40氯化钠注射液联合低分子肝素钙治疗进展性脑梗死的疗效更加显著,安全性更高,不良反应较少,值得临床推广应用。
Objective To investigate the clinical efficacy of hydroxyethyl starch 40 sodium chloride injection in patients with advanced cerebral infarction. Methods Sixty patients with progressive cerebral infarction were divided into control group (treated with conventional therapy) and combination therapy group (treated with hydroxyethyl starch 40 sodium chloride injection combined with low molecular weight Heparin calcium treatment), 30 cases in each group. The National Institutes of Health Stroke Scale (NIHSS) score, Barthel Index, treatment outcome, and incidence of adverse events were compared between the two groups before and after treatment. Results Before treatment, there was no significant difference in NIHSS score between the two groups (P> 0.05). At 7 and 14 days after treatment, the NIHSS scores in the combined treatment group were lower than those in the control group, with statistical significance (P <0.05). Before treatment, there was no significant difference in Barthel index between the two groups (P> 0.05). At 3 and 6 months after treatment, the Barthel index in the combined treatment group was higher than that in the control group, with statistical significance (P <0.05). The total effective rate was 96.7% in the combined treatment group, which was higher than that in the control group (80.0%), the difference was statistically significant (P <0.05). The incidence of adverse reactions in the combined treatment group was 3.3%, which was lower than that in the control group (20.0%), the difference was statistically significant (P <0.05). Conclusion The therapeutic effect of hydroxyethyl starch 40 sodium chloride injection combined with low molecular weight heparin on progressive cerebral infarction is more significant, more safe and less adverse reactions, which is worthy of clinical application.